Naslov
Hepcidin: a new site of action of wine in patients with diabetes mellitus type 2

Autori
Gujinović, Diana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Pharmaca 2022 ; 52 Suppl 2: 1-236 / Mršić-Pelčić, Jasenka ; Vitezić, Dinko ; Janković, Tamara - Zagreb, 2022, 83-83

Skup
10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation

Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
type 2 diabetes mellitus ; red wine ; iron ; hepcidin

Sažetak
Type 2 diabetes (T2D) is a complex and multifactorial disease, requiring the orchestration of pharmacological and nonpharmacological treatment approaches. Along with low-grade chronic inflammation, T2D is often associated with iron overload. This indicates a potential role of hepcidin, the key iron-regulatory hormone and acute-phase protein, in the pathogenesis of T2D. Hepcidin reduces iron bioavailability by promoting the degradation of ferroportin, the only mammalian iron exporter identified to date. According to the evidence, alcohol consumption may also lead to body iron excess. On the other side, moderate consumption of red wine, an important component of the Mediterranean dietary pattern, has been associated with the cardiometabolic benefits in T2D. These effects have been mainly attributed to both ethanol and polyphenolic compounds, that are present in particularly high content in red wine. In this lecture it will be discussed how changes in hepcidin levels associated with moderate consumption of wine might influence wine’s cardiometabolic effects.

Izvorni jezik
Engleski

POVEZANOST RADA